Motley Fool Asset Management LLC Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Motley Fool Asset Management LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,342 shares of the biopharmaceutical company’s stock after acquiring an additional 1,163 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Gilead Sciences were worth $2,348,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. OLD Second National Bank of Aurora lifted its stake in shares of Gilead Sciences by 46.3% in the 3rd quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 139 shares during the period. Impax Asset Management Group plc lifted its stake in shares of Gilead Sciences by 0.4% in the 3rd quarter. Impax Asset Management Group plc now owns 40,201 shares of the biopharmaceutical company’s stock worth $2,808,000 after purchasing an additional 149 shares during the period. Key Financial Inc boosted its holdings in Gilead Sciences by 3.7% in the 4th quarter. Key Financial Inc now owns 4,228 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 151 shares during the period. Trust Investment Advisors boosted its holdings in Gilead Sciences by 1.3% in the 4th quarter. Trust Investment Advisors now owns 12,243 shares of the biopharmaceutical company’s stock worth $889,000 after buying an additional 153 shares during the period. Finally, Equitable Holdings Inc. boosted its holdings in Gilead Sciences by 0.4% in the 3rd quarter. Equitable Holdings Inc. now owns 41,253 shares of the biopharmaceutical company’s stock worth $2,882,000 after buying an additional 156 shares during the period. 80.16% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction on Friday, March 11th. The shares were sold at an average price of $58.24, for a total value of $211,644.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

GILD has been the topic of a number of research analyst reports. Mizuho dropped their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “buy” rating on the stock in a research note on Tuesday, February 8th. Truist Financial cut their price target on shares of Gilead Sciences from $77.00 to $75.00 and set a “hold” rating on the stock in a report on Wednesday, February 2nd. BMO Capital Markets assumed coverage on Gilead Sciences in a research report on Tuesday, March 8th. They set a “hold” rating and a $65.00 target price on the stock. Barclays dropped their price target on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating on the stock in a research note on Thursday, March 10th. Finally, Maxim Group lowered their target price on Gilead Sciences from $88.00 to $84.00 in a research note on Thursday, February 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and an average target price of $72.67.

Shares of GILD traded up $0.54 on Tuesday, hitting $62.78. 175,246 shares of the stock traded hands, compared to its average volume of 8,514,530. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $78.75 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.44 and a beta of 0.38. The stock’s 50 day moving average is $60.67 and its two-hundred day moving average is $65.23. Gilead Sciences, Inc. has a 1 year low of $57.19 and a 1 year high of $74.12.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.35. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. Gilead Sciences’s revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.08 earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post 6.62 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th will be paid a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a yield of 4.65%. The ex-dividend date is Tuesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 81.56%.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Recommended Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.